Radiopharm Theranostics
RADX
3 hedge funds and large institutions have $1.65M invested in Radiopharm Theranostics in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.02% → 0.01% (-0.01%)
15% less capital invested
Capital invested by funds: $1.94M → $1.65M (-$290K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$476K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.91K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Silverarc Capital Management
Boston,
Massachusetts
| $901K | – | – | – |
|
|
RP
2
Regal Partners
Sydney, NSW,
Australia
| $437K | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $311K | -$476K | -91,571 | -59% |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$5.91K | -1,317 | Closed |
|
RADX Hedge Fund Activity: Q1 2025 in Review
3 of the 7,462 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q1 2025, worth a combined $1.65M — down 15% from $1.94M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RADX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Affinity Asset Advisors, cutting an estimated $476K.
- 3 institutional investors held Radiopharm Theranostics (RADX) as of Q1 2025, down from 4 in Q4 2024.
- Funds reported $1.65M of Radiopharm Theranostics stock for Q1 2025, down 15% quarter-over-quarter.
- 0 funds opened new Radiopharm Theranostics positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest Radiopharm Theranostics seller in Q1 2025 was Affinity Asset Advisors, an estimated $476K sold.
Based on aggregated 13F filings for Q1 2025.